【JCR Pharma】Financial Results and Partnership Details for the Fiscal Year Ending June 2026｜June 2026

Performance Overview

JCR Pharma announced its financial results for the fiscal year ending June 2026, continuing its capital partnership with its parent company Medipal Holdings. Medipal is the largest shareholder with a voting rights ratio of 23.86%, and both companies are advancing business initiatives that leverage their respective strengths. The report also includes progress on agreements for the overseas commercialization of its new drug candidates and developments in treatments for rare diseases.

Future Outlook and Impact on Shareholders

The company will continue to integrate drug discovery and sales capabilities to expand its business. Through collaboration with Medipal, it aims to promote overseas expansion of treatments for rare diseases and the commercialization of new drug candidates, striving to enhance long-term corporate value. For shareholders, strengthened partnerships and advancements in new drug development are expected to be key drivers of growth.